Date: 2016-07-04
Type of information: Construction of new premises
Compound: extension of a production plant
Company: Novo Nordisk (Denmark)
Therapeutic area: Metabolic diseases
Type agreement: construction of new premises
Action mechanism:
Disease:
Details: * On July 4, 2016, Novo Nordisk announced that the company is investing 400 million Danish kroner (€ 53.7 million) in a 500 m2 extension of the world's largest insulin production plant in Kalundborg (Denmark). Established in 1969, the Kalundborg production site covers a total area of 1.1 million square metres. With its 3,400 employees, Novo Nordisk Kalundborg is a cornerstone of Novo Nordisk's global production and produces 50% of the world's insulin as well as a range of biopharmaceutical products. The extension is expected to be completed at the end of 2018.
Financial terms:
Latest news:
